Alcohol use disorders and associated chronic disease – a national retrospective cohort study from France

Michaël Schwarzinger, Sophie Pascale Thiébaut, Sylvain Baillot, Vincent Mallet and Jürgen Rehm

Abstract

Background: Evidence on diseases caused by or associated with alcohol use disorders (AUDs) has been based on two meta-analyses including rather dated studies. The objective of this contribution was to estimate the risks of all-cause mortality and alcohol-attributable disease categories depending on a diagnosis of AUDs in a national sample for France.

Methods: In a national retrospective cohort study on all inpatient acute and rehabilitation care patients in Metropolitan France 2008–2012 (N = 26,356,361), AUDs and other disease categories were identified from all discharge diagnoses according to standard definitions, and we relied on in-hospital death for mortality (57.4% of all deaths).

Results: 704,803 (2.7%) patients identified with AUDs had a threefold higher risk of death (HR = 2.98; 95% CI: 2.96–3.00) and died on average 12.2 years younger (men: 10.4, 95% CI: 10.3–10.5; women: 13.7, 95% CI: 13.6–13.9). AUDs were associated with significantly higher risks of hospital admission for all alcohol-attributable disease categories: digestive diseases, cancers (exception: breast cancer), cardiovascular diseases, dementia, infectious diseases, and injuries. Elevated risks were highest for liver diseases that were associated with about two-third of deaths in patients with AUDs (men: 64.3%; women: 71.1%).

Conclusions: AUDs were associated with marked premature mortality and higher risks of alcohol-attributable disease categories. Our results support the urgent need of measures to reduce the burden of AUDs.

Keywords: Alcohol use disorders, Risk factor, Mortality, Non-communicable disease, Burden of disease

Introduction

Background/rationale

Alcohol use is a major risk factor for burden of disease and injury [1, 2]. Alcohol use disorders (AUDs), defined as alcohol dependence and harmful use of alcohol (cf. International Classification of Disease tenth revision (ICD-10) [3]), contribute markedly to this burden [4, 5]. In the European Union, in 2004, alcohol dependence, the most severe disabling of AUDs, was estimated to account for 62% of all burden from alcohol use [4].

This contribution aims to quantify the hospitalization and mortality risks associated with AUD for all disease categories are causally related to alcohol, i.e., assuming level of ethanol exposure as the pathway between AUD and outcomes (general: [6]; for risk analyses of ethanol e.g.: [7, 8]). Under this assumption, all conditions causally impacted by either chronic or episodic heavy alcohol use [9–11] would be relevant: all alcohol-attributable cancers [12]; liver cirrhosis [9], acute and chronic pancreatitis [13] as digestive diseases; ischemic heart disease [14], congestive heart disease [15], atrial fibrillation [16], stroke [17], as cardiovascular diseases; and pneumonia [18] and tuberculosis [19] as infectious diseases; and both intentional and unintentional injury [20]. Mental disorders are not on this list, as causality is not clear and quantification of the causal impact of alcohol or alcohol
use disorders has not yet been achieved [21]. Alzheimer’s disease and other forms of dementia may be an exception there. On the one hand, there is a possible protective effect of light to moderate drinking [22, 23]. On the other hand, several subtypes of dementia are clearly detrimentally and causally related to heavy drinking [24], and the most recent review exhibited a J- or U-shaped relationship between the intensity of alcohol consumption and the sign of the effect [25]. We included dementia in our list for quantification, even though in prior comparative risk analyses for alcohol, this condition was excluded [1, 26, 27].

Two meta-analyses of cause-specific mortality risks of AUDs corroborated the above list [28, 29]. Two points related to these two meta-analyses deserve to be mentioned. Firstly, most of the evidence on diseases caused or associated with AUDs was rather old, and secondly, significant heterogeneity was found between study results.

Objective
Based on this background, the main objective was to estimate the hospitalization and mortality risks of all-cause mortality and alcohol-attributable disease categories depending on a diagnosis of AUDs in a national sample for France.

Methods
Data source
Main data source was the French National Hospital Discharge database (Programme de Médicalisation des Systèmes d’Information) which contains all public and private claims for inpatient acute and rehabilitation care since 2008 [30]. The standardized discharge summary includes: patient’s demographics; primary and associated discharge diagnosis codes according to WHO International Classification of Diseases, tenth revision (ICD-10, French version); medical procedures performed (French Medical Common Procedure Coding System); length of stay, entry and discharge modes (including in-hospital death). The French National Hospital Discharge database was analysed with de-identified patient information for the years 2008 to 2012. The unique anonymous identifier allows linking all hospital claims of the patient and tracking the occurrence and progression of severe conditions over time.

Study population
Out of 28,953,755 adults residing in Metropolitan France with at least one hospital record in the 2008–2012 National Hospital Discharge database, we excluded 2,597,394 (9.0%) women only admitted for delivery care or abortion during the study period.

Alcohol use disorders
Patients with AUDs were identified by any hospital record describing mental and behavioural states due to former or current harmful use of alcohol (ICD-10 F10.1 to F10.9) or ICD-10 codes indicating a disease onset that is fully attributable to AUDs (e.g., K70 ‘Alcoholic Liver Disease’). Individuals identified with AUDs were further categorized as ‘abstinent’ if they had any hospital record of abstinence in the years 2008–2012 (see Additional file 1: Table S1 for ICD-10 codes used).

Alcohol-attributable disease categories
We investigated risk relationships between AUDs and alcohol-attributable disease categories requiring hospital care: 1) liver diseases (cirrhosis and liver cancer); 2) pancreatic diseases (acute and chronic pancreatitis, pancreatic cancer); 3) upper aerodigestive tract cancer (oral cavity, oropharynx, hypopharynx, larynx, and oesophageal cancers); 4) other cancers (colorectal or breast cancers); 5) cardiovascular diseases (ischemic heart diseases, congestive heart failure, atrial fibrillation, and cerebrovascular diseases disentangling ischemic or haemorrhagic stroke); 6) dementia; 7) infectious diseases (pneumococcal pneumonia, and tuberculosis); and 8) injuries (non-intentional injury, self-harm, and other intentional injury). Disease categories were defined by the presence of ICD-10 codes as primary or associated discharge diagnosis, and ICD-10 codes were selected to concur with the definitions used in GLOBOCAN (http://globocan.iarc.fr/Default.aspx), the Global Burden of Disease study, or the Charlson Comorbidity Index (see Additional file 1: Table S1 for ICD-10 codes used).

Statistical analysis
All-cause mortality risk and cause-specific risks of hospital admission were estimated in Cox proportional hazards models with left truncation and right censoring. For all-cause mortality risk, we used age as the timescale to estimate the effect of AUDs over lifetime with universal follow-up of the French adult population from January 1st, 2008, until death or last discharge in 2008–2012 [31]. For each cause-specific risk of hospital admission, we used similarly age as the time-scale from January 1st, 2008, until first hospital record of the disease category, death, or last discharge in 2008–2012. All Cox models were stratified on gender, five main French regions (North-West, North-East, Greater Paris area, South-West, South-East), and having received care in a tertiary care center (public teaching hospital or comprehensive cancer care centre) since Schoenfeld residuals tests pointed out non proportionality of the effects for these variables.
The effect of AUDs over lifetime was suspected to be non-proportional as AUDs are likely to have different effects at different ages, either because of the frailty of patients with AUDs or because age indicates the duration of exposure to alcohol. We examined hazard ratios under two assumptions: (i) one binary variable of AUDs status was introduced under the assumption of linearity of the effect of AUDs over lifetime; (ii) an age-varying effect of AUDs was estimated by introducing a third order polynomial of age. All analyses were performed with Statistical Analysis System (SAS 9.4).

Potential sources of bias for mortality calculations
While most alcohol-attributable disease categories require hospital care and thus were covered by our national hospital data sources, the main concern about the validity of mortality estimation was related to the likelihood of an individual to die at hospital. While the majority of French die in the hospital (57.4%, see below), bias may be introduced especially if the people dying in a hospital are different from the people dying outside. If dying inside or outside the hospital is a random process then our sample did not suffer from selection bias for mortality estimation (i.e., the absolute numbers will be underestimated, but the relationships will be correct). Otherwise, if the place of death is related to health status, then dedicated analyses may be necessary to exclude such bias. While we cannot control for health status directly, we examined the likelihood of bias via a proxy variable of health status, premature mortality (≤65 years) by gender.

External data sources (National Vital Statistics based on death certificates) indicate that a total of 2,672,906 adults residing in Metropolitan France died between 2008 and 2012. Overall, 1,535,185 (57.4%) deaths were recorded at hospital and thus were covered by our data sources. Premature mortality was more marked in men than women (27.5% of 1,355,892 men versus 13.3% of 1,317,014 women). Death was recorded at hospital in about the same proportions for premature and other mortality (58.8% and 57.1%, respectively), indicating no bias. Opposite trends were found by gender (men: 56.1% versus 62.1%; women: 64.7% versus 52.8%) as explained by increasing proportions of deaths recorded in nursing home with an older age. Consequently, all analyses were conducted separately by sex, and sensitivity analyses were performed on the presence of alcohol-attributable disease categories before death depending on premature mortality.

Results
All-cause mortality risk
Table 1 gives an overview of baseline characteristics of the sample, prevalence of AUD and associated in-hospital death rates. Overall, 704,803 (2.7%) patients identified with AUDs had a threefold higher risk of death (hazard

| Characteristics | All Adults | In-Hospital Death, n (%) | Men | In-Hospital Death, n (%) | Women | In-Hospital Death, n (%) |
|-----------------|------------|--------------------------|-----|--------------------------|-------|--------------------------|
| Age at cohort inception (Jan. 1st, 2008) in years | 26,356,361 (100) | 1,506,334 (5.7) | 12,300,516 (46.7) | 816,259 (6.6) | 14,055,845 (53.3) | 690,075 (4.9) |
| < 30 | 4,687,102 (17.8) | 11,077 (0.2) | 2,255,316 (18.3) | 7053 (0.3) | 2,431,786 (17.3) | 4024 (0.2) |
| 30–39 | 3,206,919 (12.2) | 19,546 (0.6) | 1,476,922 (12.0) | 10,888 (0.7) | 1,729,997 (12.3) | 8658 (0.5) |
| 40–49 | 4,007,783 (15.2) | 67,554 (1.7) | 1,902,807 (15.5) | 40,517 (2.1) | 2,104,976 (15.0) | 27,037 (1.3) |
| 50–59 | 4,658,741 (17.7) | 167,946 (3.6) | 2,336,423 (19.0) | 111,321 (4.8) | 2,322,318 (16.5) | 56,625 (2.4) |
| 60–69 | 3,782,817 (14.4) | 222,356 (5.9) | 1,894,887 (15.4) | 145,912 (7.7) | 1,887,930 (13.4) | 76,444 (4.1) |
| 70–79 | 3,603,656 (13.7) | 426,766 (11.8) | 1,605,710 (13.1) | 247,181 (15.4) | 1,997,946 (14.2) | 179,585 (9.0) |
| 80–89 | 2,108,262 (8.0) | 491,158 (23.3) | 754,991 (6.1) | 223,228 (29.6) | 1,353,271 (9.6) | 267,930 (19.8) |
| ≥ 90 | 301,081 (1.1) | 99,931 (33.2) | 73,460 (0.6) | 30,159 (41.1) | 227,621 (1.6) | 69,772 (30.7) |
| Region of residency in Metropolitan France | | | | | | |
| Greater Paris area | 4,450,245 (16.9) | 217,573 (4.9) | 2,014,604 (16.4) | 113,952 (5.7) | 2,435,641 (17.3) | 103,621 (4.3) |
| North-West | 6,051,875 (23.0) | 373,476 (6.2) | 2,849,253 (23.2) | 206,088 (7.2) | 3,202,622 (22.8) | 167,388 (5.2) |
| North-East | 6,023,280 (22.9) | 372,947 (6.2) | 2,806,326 (22.8) | 200,203 (7.1) | 3,216,954 (22.9) | 172,744 (5.4) |
| South-West | 3,080,671 (11.7) | 175,921 (5.7) | 1,452,170 (11.8) | 95,699 (6.6) | 1,628,501 (11.6) | 80,222 (4.9) |
| South-East | 6750,290 (25.6) | 366,417 (5.4) | 3,178,163 (25.8) | 200,317 (6.3) | 3,572,127 (25.4) | 166,100 (4.7) |
| Tertiary care center | 6,458,321 (24.5) | 595,896 (9.2) | 3,040,223 (24.7) | 337,187 (11.1) | 3,418,098 (24.3) | 258,706 (7.6) |
| Alcohol Use Disorders | 704,803 (2.7) | 112,752 (16.0) | 528,480 (4.3) | 89,165 (16.9) | 176,323 (1.3) | 23,587 (13.4) |
ratio (HR = 2.98, 95% CI: 2.96–3.00) compared to all other adults discharged from French hospitals in 2008–2012. One-quarter of patients with AUDs were women with a higher risk of death (HR = 3.30, 95% CI: 3.25–3.34 compared to HR = 2.90, 95% CI: 2.88–2.92 for men). The instantaneous risk of death with AUDs was not proportional over lifetime: it increased sharply from age 20 to 53 (2.15 to 4.92 in women; 1.98 to 3.97 in men) and remained significantly above 1 until age 86 (Fig. 1).

Cause-specific risks of hospital admission
Tables 2 and 3 give the hazard ratios for alcohol-attributable disease categories in men and women, respectively. In both gender, AUDs were associated with significantly higher risks for all alcohol-attributable disease categories, including colorectal cancer but not breast cancer.

Elevated risks were highest for digestive disease categories, followed by upper aerodigestive tract cancers, dementia, injuries, and infectious diseases. No protective effects was found in any cardiovascular diseases with hazard ratios varying between 1.11 (95% CI: 1.10–1.12) for ischemic heart disease in men and 2.66 (95% CI: 2.58–2.75) for haemorrhagic and non-ischemic stroke in women. Hazard ratios were not proportional over lifetime (Additional file 1: Figs. S1–S21): they were all bell-shaped around an earlier onset of each disease category with exception of ischemic heart disease in men (flat risk over lifetime), colorectal and breast cancers (both showing later onset in AUDs’ survivors).

Presence of alcohol-attributable disease categories at death and age at death
Table 4 gives all alcohol-attributable disease categories recorded before death and age at death for 1,506,334 adult patients dying at French hospitals in 2008–2012. AUDs were recorded in 112,752 (7.5%) deceased patients (men: 10.9%; women: 3.4%). One or more alcohol-attributable disease categories were found in 93.2% deceased patients with AUDs, with liver diseases recorded in about two-third patients (64.3% in men; 71.1% in women). Similar proportions were found by gender depending on premature mortality (Additional file 1: Tables S2 and S3). Overall, the average age at death was 64.9 years for patients with AUDs, i.e., 12.2 years younger than other adults dying at hospital without AUDs (men: 10.4 years, 95% CI: 10.3–10.5; women: 13.7 years, 95% CI: 13.6–13.9).

Discussion
AUDs were associated with marked premature mortality and higher risks of hospitalization for alcohol-attributable disease categories. The hazard ratio for all-cause mortality was threefold (HR = 2.98; 95% CI: 2.96–3.00), with patients with AUDs dying on average 12.2 years younger (men: 10.4, 95% CI: 10.3–10.5; women: 13.7, 95% CI: 13.6–13.9). It should be noted that the relative risks and life expectancy measures were in comparison to other people visiting the hospital, whereas many prior studies used standardized mortality ratios, which would include the whole population including those who did not go to the hospital during the period examined [28, 29, 32, 33]. Despite this difference, the relative risks found are comparable to the relative risks found in the meta-analyses of studies based on standardized mortality ratios [29, 32].

Our study found higher relative all-cause mortality risk for women with AUDs than for men, even though their drinking level has been shown to be lower in terms of average consumption of pure alcohol per day [34, 35]. The reason for this can be found in the different alcohol metabolism, leading to higher blood alcohol concentration in women [36]. Elevated risks of hospital admission
were highest for liver diseases that eventually accounted for about two-third of deaths recorded among patients with AUDs. AUDs were associated with significantly higher risks of hospital admission for all other alcohol-attributable disease categories except breast cancer. This confirms scarce results from earlier studies [28, 29], including results on increased risks for ischemic heart disease and other cardiovascular risk factors in a nationwide study [14]. Among patients with AUDs, any hospital record of abstinence was associated with a substantially reduced all-cause mortality risk by 34.5% (95% CI: 33.3–35.7).

The French healthcare system provides universal access to hospital care. This national retrospective cohort study eventually involved 51.9% of the total adult population residing in Metropolitan France by January 2008. It is by far the largest and most complete study relating AUDs to disease and injury outcomes. The French National Hospital Discharge database has been shown to be complete and of good quality [30]. In particular, records of in-hospital deaths are close between the National Hospital Discharge database and National Vital Statistics based on death certificates, and account for about 57% of all deaths in 2008–2012 in France [37, 38]. Deaths outside the hospital may be seen as a limitation of the study, as it cannot be excluded that systematic bias had been introduced this way. However, the majority of deaths were in the hospital in all age groups, with no indication of a strong bias by age (see Additional file 1: Tables S2 and S3).

A weakness is the operationalization of the independent variable, AUDs. As this operationalization is based on discharge records, it can only measure AUDs which

| Alcohol-Attributable Disease Category | Total, n (%) | AUDs, n (%) | Mean (SD) age at incidence | Hazard Ratio with AUDs (95% CI) |
|--------------------------------------|--------------|-------------|----------------------------|-------------------------------|
|                                      |              | AUDs | No AUDs                  |                               |
| Liver diseases                       |              |      |                          |                               |
| Cirrhosis                            | 357,809 (2.91) | 155,000 (43.3) | 59.6 (12.0) | 64.9 (16.6) | 15.97 (15.86–16.09) |
| Liver cancer                         | 56,162 (0.46)  | 26,199 (46.7)  | 65.3 (9.9)  | 69.6 (12.4) | 16.12 (15.84–16.40) |
| Pancreatic diseases                  |              |      |                          |                               |
| Acute pancreatitis                   | 80,860 (0.66)  | 32,711 (40.5)  | 48.8 (13.2) | 60.7 (18.0) | 12.14 (11.96–12.32) |
| Chronic pancreatitis                 | 57,465 (0.47)  | 31,602 (55.0)  | 53.2 (12.3) | 62.3 (16.1) | 20.36 (20.01–20.71) |
| Pancreatic cancer                    | 41,853 (0.34)  | 3659 (8.7)     | 62.2 (10.9) | 68.6 (12.0) | 1.61 (1.56–1.67)    |
| Upper aerodigestive tract cancers    |              |      |                          |                               |
| Head and neck cancer                 | 82,852 (0.67)  | 19,875 (24.0)  | 57.8 (8.7)  | 63.2 (11.9) | 4.39 (4.31–4.46)    |
| Larynx cancer                        | 37,952 (0.31)  | 8399 (22.1)    | 59.0 (8.9)  | 64.9 (11.1) | 4.03 (3.93–4.14)    |
| Oesophageal cancer                   | 36,083 (0.29)  | 6084 (16.9)    | 60.7 (9.4)  | 66.8 (11.5) | 3.19 (3.10–3.32)    |
| Colorectal cancer                    | 190,593 (1.55) | 10,427 (5.5)   | 65.7 (10.3) | 69.5 (12.2) | 1.14 (1.11–1.16)    |
| Cardiovascular diseases              |              |      |                          |                               |
| Ischemic heart disease               | 1,290,533 (10.49) | 71,137 (5.5) | 62.6 (11.5) | 68.8 (12.8) | 1.11 (1.10–1.12) |
| Congestive heart failure             | 980,140 (8.0)  | 76,602 (7.8)   | 64.4 (12.1) | 73.4 (12.8) | 1.95 (1.94–1.97) |
| Atrial fibrillation                  | 898,455 (7.30) | 54,639 (6.1)  | 67.5 (11.5) | 74.4 (11.9) | 1.64 (1.63–1.66) |
| Ischemic stroke                      | 432,393 (3.52) | 34,288 (7.9)  | 63.8 (11.4) | 71.3 (13.0) | 1.75 (1.73–1.77) |
| Haemorrhagic and other non-ischemic  | 108,219 (0.88) | 12,164 (11.2) | 59.6 (12.7) | 67.9 (16.9) | 2.23 (2.19–2.28) |
| Dementia                             | 389,687 (3.17) | 47,349 (12.2) | 65.6 (13.2) | 80.5 (9.1)  | 4.67 (4.63–4.72) |
| Infectious diseases                  |              |      |                          |                               |
| Pneumococcal pneumonia               | 28,569 (0.23)  | 4799 (16.8)    | 56.4 (12.9) | 64.7 (18.6) | 3.71 (3.60–3.83) |
| Tuberculosis                         | 42,945 (0.35)  | 4524 (10.5)    | 57.4 (13.3) | 61.8 (20.3) | 2.22 (2.15–2.29) |
| Injuries                             |              |      |                          |                               |
| Non-intentional injury               | 357,461 (2.91) | 42,425 (11.9) | 56.7 (15.6) | 56.5 (24.1) | 3.11 (3.08–3.15) |
| Self-harm                            | 144,723 (1.18) | 36,548 (25.3) | 43.1 (12.0) | 39.4 (17.1) | 6.55 (6.47–6.64) |
| Other intentional injury             | 32,113 (0.26)  | 5966 (18.6)    | 43.7 (21.9) | 36.7 (18.3) | 5.02 (4.88–5.17) |
were recognised and assessed at hospital. Given that AUDs are highly stigmatized [39] with low treatments rates in Europe (around 10% in recent studies [4, 40]), it is likely that only the more severe AUDs were identified, which would mean that the overall impact of AUDs and heavy drinking was underestimated in our analyses. This conclusion is also likely comparing the proportion of adults with AUDs in the hospital discharge database (2.7%) with the prevalence estimated in epidemiological studies (estimate of 6% for France; 3.4% for alcohol dependence alone [41]).

As indicated above, the current study is by far the largest study on the risks for diseases subsequent to AUDs. In general, results corroborated the hypotheses based on epidemiological studies for heavy drinking, with exception of breast cancer. This latter result is puzzling as alcohol consumption has been shown to impact on breast cancer consistently over adult life-course in a dose-response relationship [42, 43]. However, the relative risks found in meta-analyses and large studies for breast cancer were among the lowest of all alcohol-attributable cancers (most risks for heavy drinking around 1.5 [43, 44]). As evidenced by our study, the high level of competing risks in patients with AUDs, i.e. other alcohol-attributable conditions and premature death, and the long lag time for developing breast cancer seem to be an explanation.

Results showed, that co-morbidity of alcohol-attributable diseases was high at death. However, potential interactions between AUD and other co-morbid disorders on risk have not been modelled in the current study.

### Table 3: Hazard Ratios for Alcohol-Attributable Disease Categories in 14,055,845 Women (French National Hospital Discharge database 2008–2012)

| Alcohol-Attributable Disease Category | Total, n (%) | AUDs, n (%) | Mean (SD) age at incidence | Hazard Ratio with AUDs (95% CI) |
|--------------------------------------|--------------|-------------|---------------------------|-----------------------------|
|                                      |              | AUDs No AUDs |              |                              |
| Liver diseases                       |              |             |                       |                             |
| Cirrhosis                           | 250,148 (1.78)| 52,348 (20.9)| 60.2 (12.5) | 65.6 (18.3) | 19.28 (10.09–19.47) |
| Liver cancer                         | 21,171 (0.15) | 3690 (17.4) | 66.4 (11.2) | 71.7 (13.8) | 13.24 (12.76–13.73) |
| Pancreatic diseases                  |              |             |             |                             |                             |
| Acute pancreatitis                   | 59,304 (0.42)| 6737 (11.4) | 50.4 (14.2) | 61.1 (20.9) | 8.56 (8.34–8.78) |
| Chronic pancreatitis                 | 32,289 (0.23)| 6490 (20.1) | 54.0 (13.3) | 64.2 (17.8) | 13.24 (12.76–13.73) |
| Pancreatic cancer                    | 38,627 (0.23)| 858 (2.2)   | 63.6 (12.5) | 72.0 (13.2) | 1.44 (1.35–1.54) |
| Upper aerodigestive tract cancers    |              |             |             |                             |                             |
| Head and neck cancer                 | 24,814 (0.18)| 3255 (13.1) | 56.9 (9.0)  | 65.3 (14.9) | 7.54 (7.26–7.83) |
| Larynx cancer                        | 5267 (0.04)  | 924 (17.5)  | 57.6 (8.7)  | 63.9 (13.0) | 9.68 (9.00–10.41) |
| Esophageal cancer                    | 9399 (0.07)  | 926 (9.9)   | 61.0 (9.6)  | 69.8 (13.2) | 6.23 (5.81–6.67) |
| Colorectal cancer                    | 165,510 (1.18)| 2584 (1.6) | 67.3 (11.1) | 71.2 (13.7) | 1.09 (1.05–1.14) |
| Breast cancer                        | 461,426 (3.28)| 6108 (1.3)  | 62.3 (11.9) | 62.6 (14.4) | 0.65 (0.63–0.67) |
| Cardiovascular diseases              |              |             |             |                             |                             |
| Ischemic heart disease               | 717,549 (5.10)| 12,170 (1.7) | 66.5 (13.1) | 76.1 (12.7) | 1.45 (1.43–1.48) |
| Congestive heart failure             | 829,405 (5.90)| 17,822 (2.2) | 68.4 (12.9) | 80.0 (11.6) | 2.35 (2.32–2.39) |
| Atrial fibrillation                  | 818,585 (5.82)| 13,547 (1.7) | 71.9 (10.8) | 79.9 (10.4) | 1.84 (1.81–1.87) |
| Ischemic stroke                      | 377,120 (2.68)| 8562 (2.3)  | 65.9 (12.9) | 75.8 (14.2) | 1.92 (1.88–1.97) |
| Hemorrhagic and other non-ischemic stroke | 100,700 (0.72)| 3864 (3.8)  | 61.3 (13.1) | 72.0 (16.8) | 2.66 (2.58–2.75) |
| Dementia                             | 675,778 (4.81)| 19,720 (2.9) | 69.4 (13.3) | 83.3 (8.1)  | 4.27 (4.21–4.33) |
| Infectious diseases                  |              |             |             |                             |                             |
| Pneumococcal pneumonia               | 20,642 (0.15)| 1193 (5.8) | 55.5 (13.5) | 67.5 (20.0) | 4.35 (4.10–4.62) |
| Tuberculosis                         | 36,103 (0.26)| 889 (2.5) | 59.8 (15.0) | 65.7 (20.8) | 1.80 (1.68–1.92) |
| Injuries                             |              |             |             |                             |                             |
| Non-intentional injury               | 404,365 (2.88)| 17,364 (4.3) | 61.5 (15.2) | 71.8 (20.5) | 4.49 (4.42–4.56) |
| Self-harm                            | 223,769 (1.59)| 24,893 (11.1)| 45.2 (12.2) | 40.6 (18.0) | 8.90 (8.78–9.03) |
| Other intentional injury             | 17,958 (0.13) | 2619 (14.6) | 46.5 (13.3) | 46.5 (22.7) | 12.58 (12.05–13.13) |
Since the burden associated with AUDs has been re-confirmed in this study, efforts should be undertaken to reduce this burden. Most importantly, treatment (alcohol rehabilitation) reduced this burden regardless of long-term abstinence (see also [45] for a similar finding in a meta-analysis of mortality after reduction of drinking in AUDs). A clear implication of our study is thus to increase the treatment rate of AUDs which is the lowest for all mental disorders [40]. Currently, most recommendations about screening for alcohol are for primary health care [46]. Given the above results, these recommendations should be supplemented by better screening, interventions, and referral from acute hospitals to specialised care, or by incorporated addictions specialist services into hospitals. A Cochrane review has shown that even brief interventions in the hospital setting could reduce the one year mortality rate by 40% [47]. Being a patient in a hospital seems to be a critical moment, where awareness of the problem and motivation to reduce or abstain from alcohol consumption can be initiated. Research should be conducted to better integrate screening, brief interventions, and referral into the clinical routine of acute care hospitals. Screening may be linked to routine work of nurses [48], but it will need protected time within the routine, financial compensation, and adequate training [49]. Implementation trials are needed to identify the best strategy to achieve these goals. Finally, given the large overall impact, proven alcohol policy measures to reduce the harmful effects of drinking should be reinforced [50, 51].

### Conclusions

AUD were highly associated with hospitalizations and premature death in most disease and injury categories which had been identified as partially caused by alcohol use, creating a high burden. Interventions should be implemented to reduce this burden.

### Additional file

**Additional file 1:** Additional Tables and Figures for Alcohol use disorders and associated chronic disease – a national retrospective cohort study from France. (DOCX 1775 kb)

### Abbreviations

AUD: Alcohol use disorders; CI: Confidence interval; HR: Hazard ratio; ICD: WHO International Classification of Diseases; n: number of people; SD: Standard deviation

### Acknowledgements

None.

### Funding

The study did not receive any external funding.

### Availability of data and materials

The data are in principle accessible from the “Agence technique de l’information sur l’hospitalisation” (for details: http://www.atih.sante.fr/acces-aux-donnees).

### Authors’ contributions

MS initiated the study, contributed to the analysis and interpretation of the data, and wrote the first draft of the paper. He is the guarantor. SPT performed primary data analyses, contributed to the interpretation of the data and drafting of the paper. SB coordinated the database engineering work, contributed to the analysis and interpretation of the data. VM contributed to the analysis and interpretation of the data, and drafting of the paper. JR helped conceptualize the study, contributed to the analysis.

### Table 4 Alcohol-Attributable Disease Categories at Death, by gender and AUDs status (French National Hospital Discharge database 2008–2012)

| Alcohol-attributable disease categories | Men (n = 816,259) | Women (n = 690,194) |
|----------------------------------------|-------------------|---------------------|
|                                        | AUDs, n (%)       | Mean (SD) age at death AUDs, n (%) | No AUDs, n (%) | Mean (SD) age at death |
|                                        | (9.9)             | AUDs           | No AUDs                      | AUDs, n (%) |
|                                        | 89,165 (10.9)     | 64.8 (11.7)    | 75.2 (13.3)                  | 23,587 (3.4) |
|                                        | 727,094 (89.1)    | 666,607 (96.6) | 65.5 (12.7)                  | 79.2 (13.4) |
| One or more disease categories          | 83,039 (93.1)     | 65.0 (11.6)    | 76.7 (12.4)                  | 22,064 (93.5) |
|                                        | 552,314 (76.0)    | 503,466 (75.5) | 65.8 (12.6)                  | 81.0 (12.1) |
| Liver diseases                         | 57,298 (64.3)     | 64.5 (11.2)    | 71.1 (13.1)                  | 16,770 (71.1) |
|                                        | 92,547 (12.7)     | 82,348 (12.4)  | 64.7 (12.0)                  | 72.5 (14.1) |
| Pancreatic diseases                    | 8372 (9.4)        | 61.8 (11.9)    | 71.4 (12.1)                  | 1812 (7.7) |
|                                        | 30,672 (4.2)      | 28,149 (4.2)   | 62.2 (13.3)                  | 75.5 (12.3) |
| Upper aerodigestive tract cancer       | 11,552 (13.0)     | 61.4 (9.3)     | 67.9 (11.7)                  | 1685 (7.1) |
|                                        | 42,250 (5.8)      | 10,455 (1.6)   | 60.5 (9.5)                   | 71.2 (13.5) |
| Colorectal cancer                      | 3952 (4.4)        | 68.8 (10.0)    | 74.5 (11.4)                  | 872 (3.7) |
|                                        | 51,606 (7.1)      | 42,223 (6.3)   | 70.4 (10.5)                  | 76.7 (12.5) |
| Cardiovascular diseases                | 39,057 (43.8)     | 66.8 (11.2)    | 78.8 (11.0)                  | 9291 (39.4) |
|                                        | 406,023 (55.8)    | 362,751 (54.0) | 70.5 (12.2)                  | 83.3 (10.2) |
| Dementia                               | 13,557 (15.2)     | 69.7 (12.1)    | 83.3 (7.7)                   | 4406 (18.7) |
|                                        | 102,203 (14.1)    | 129,161 (19.4) | 71.5 (12.7)                  | 86.1 (7.2) |
| Infectious diseases                    | 2384 (2.7)        | 63.3 (12.2)    | 75.5 (12.8)                  | 509 (2.2) |
|                                        | 14,298 (2.0)      | 9751 (1.5)     | 63.5 (13.6)                  | 79.6 (12.5) |
| Non-intentional injury                 | 6750 (7.6)        | 67.7 (12.4)    | 79.2 (13.4)                  | 2280 (9.7) |
|                                        | 41,903 (5.8)      | 49,764 (7.5)   | 69.8 (12.5)                  | 83.8 (10.4) |
| Intentional injury                     | 2019 (2.3)        | 60.0 (13.3)    | 64.4 (20.2)                  | 881 (3.7) |
|                                        | 5822 (0.8)        | 4824 (0.7)     | 56.2 (12.6)                  | 68.0 (19.0) |
| None of the above                      | 6126 (6.9)        | 61.0 (11.6)    | 70.3 (14.9)                  | 1523 (6.5) |
|                                        | 174,780 (24.0)    | 163,141 (24.5) | 61.0 (12.2)                  | 73.6 (15.6) |
| Breast cancer (Women)                  | 1412 (6.0)        | 62,449 (9.4)   | 67.2 (11.4)                  | 70.8 (14.4) |
and interpretation of the data, and drafting of the paper. All authors gave final approval of this version to be submitted.

Ethics approval and consent to participate
The study was approved by the French National Commission for Data Protection (CNIL DE-2013-068). The requirement for informed consent was waived because the study used de-identified data.

Consent for publication
Not applicable.

Competing interests
All authors have completed the ICMJE Competing Interest form and declare that: MS, SPT, and SB have support from THEN (Translational Health Economics Network) for the submitted work; VM has no financial or non-financial interests that may be relevant to the submitted work; JR reports grants, personal fees and past board membership (Nalmefene) for Lundbeck, outside and unrelated to the submitted work. No other relationships or activities that could appear to have influenced the submitted work are reported.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Translational Health Economics Network (THEN), 39 quai de Valmy, 75010 Paris, France. 2Institut Cochin, Université Paris Descartes, Sorbonne Paris Cité (UMR-S1016), CNRS (UMR 8104), Paris, France. 3Institut Pasteur, Centre d’Immunologie Humaine (UM520), Paris, France: Hépatology, Assistance Publique - Hôpitaux de Paris, Groupe Hospitalier Cochin Port-Royal, Paris, France. 4Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada. 5Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada. 6Addiction Policy, Dalla Lana School of Public Health, University of Toronto, 155 College Street, 6th floor, Toronto, ON M5T 3M7, Canada. 7Institute of Medical Science, University of Toronto, Faculty of Medicine, Medical Sciences Building, 1 King’s College Circle, Room 2374, Toronto, ON M5S 1A8, Canada. 8Department of Psychiatry, University of Toronto, 250 College Street, 8th floor, Toronto, ON M5T 1R8, Canada. 9Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Chemnitzer Str. 46, 01187 Dresden, Germany.

Received: 23 August 2016 Accepted: 11 July 2017

Published online: 21 July 2017

References
1. World Health Organization. Global status report on alcohol and health. Geneva, Switzerland: World Health Organization; 2014.
2. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2016;388:1659–724.
3. World Health Organization. ICD-10 classification of mental and behavioural disorders: with glossary and diagnostic criteria for research. New York, N.Y: Churchill Livingstone; 1994.
4. Rehm J, Shield KD, Gmel G, Rehm MX, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013;23(3):89–97.
5. Rehm J, Dawson D, Frick U, Gmel G, Roerecke M, Shield KD, et al. Burden of disease associated with alcohol use disorders in the United States Alcohol. Clin Exp Res. 2014;38:1068–77.
6. Rehm J, Marinet S, Anderson P, Gual A, Kraus L, Nutt DJ, et al. Defining substance use disorders: do we really need more than heavy use? Alcohol Alcohol. 2013;48:633–40.
7. Lachenmeier DW, Kanteres F, Rehm J. Epidemiology-based risk assessment using the benchmark dose/margin of exposure approach: the example of ethanol and liver cirrhosis. Int J Epidemiol. 2011;40:210–8.
8. Pfaum T, Hauserl T, Baumung C, Ackermann S, Kuballa T, Rehm J, et al. Carcinogenic compounds in alcoholic beverages: an update. Arch Toxicol. 2016;90:2349–67.
9. Rehm J, Ballunas D, BORGES GL, Graham K, Irving HM, Kehoe T, et al. The relationship between different dimensions of alcohol consumption and burden of disease - an overview. Addiction. 2010;105:817–43.
10. Shield KD, Parry C, Rehm J. Chronic diseases and conditions related to alcohol use. Alcohol Res. 2013;35:155–71.
11. Rehm J, Gmel G, Gmel G, Hasen OSM, Imtiaz S, Popova S, et al. The relationship between different dimensions of alcohol use and the burden of disease - an update. Addiction. 2017;112:968–1001.
12. International Agency for Research on Cancer. Alcohol consumption and ethyl carbamate. Monograph 96 on the evaluation of carcinogenic risks to humans. Lyon, France: International Agency for Research on Cancer; 2010.
13. Irving HM, Samokhvalov AV, Rehm J. Alcohol as a risk factor for pancreatitis. A systematic review and meta-analysis. JOP. 2009;10:367–92.
14. Roerecke M, Rehm J. Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. BMC Med. 2014;12:182.
15. Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1993:329:609–15.
16. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiov Prev Rev. 2010;17:706–12.
17. Patra J, Taylor B, Irving H, Roerecke M, Ballunas D, Mohapatra S, et al. Alcohol consumption and the risk of morbidity and mortality for different stroke types- a systematic review and meta-analysis. BMC Public Health. 2010;10:258.
18. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2010;138:1789–95.
19. Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lonrhoth K, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009:450.
20. Cherripoti C, Ye Y, Bond J, Borges G, Autonoma M, Monteiro M, et al. Alcohol attributable fraction for injury morbidity from the dose-response relationship of acute alcohol consumption: emergency department data from 18 countries. Addiction. 2015;110:1724–32.
21. Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehm N et al. Alcohol Use. In: Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. edn. Edited by Ezzati M, Lopez AD, Rodgers A, Murray CIL. Geneva, Switzerland: World Health Organization; 2004: 959–1109.
22. Letenneur L. Moderate alcohol consumption and risk of developing dementia in the elderly: the contribution of prospective studies. Ann Epidemiol. 2007;17:543–5.
23. Peters R, Peters J, Warner J, Beckett N, Bulnpit C, Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing. 2008;37:505–12.
24. Gupta S, Warner J. Alcohol-related dementia: a 21st-century silent epidemic? Br J Psychiatry. 2008;193:351–3.
25. Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;24:643.
26. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental, and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386:2287–323.
27. Rehm J, Imtiaz S. Alcohol consumption as a risk factor for global burden of disease. A narrative review. Subst Abuse Treat Prev Policy. 2016;11:137.
28. Roerecke M, Rehm J. Cause-specific mortality risk in alcohol use disorder treatment patients: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:906–19.
29. Harris EC, Barralough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.
30. Agence Technique de l’Information sur l’Hospitalisation. Aide à l’utilisation des informations de chainage. [How to use de-identified patient information]. Agence Technique de l’Information sur l’Hospitalisation. 2014. http://www.ath.sante.fr/aide-utilisation-des-informations-de-chainage Accessed 06/02/2017.

31. Kom EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72–80.

32. Roerecke M, Rehm J. Alcohol use disorders and mortality - a systematic review and meta-analysis. Addiction. 2013;108:1562–78.

33. Westman J, Wahlbeck K, Laursen TM, Gissler M, Nordenstof M, Hallgren J, et al. Mortality and life expectancy of people with alcohol use disorder in Denmark, Finland and Sweden. Acta Psychiatr Scand. 2013;131:297–306.

34. Anderson P, AllamanI A, Aubin HJ, Della Vedova R, Elekes Z, Frick U, et al. People with alcohol use disorders in specialized care in eight different European countries. Alcohol Alcohol. 2015;50:310–8.

35. Rehm J, AllamanI A, Elekes Z, Jakubczyk A, Landsmane I, Manthey J, et al. General practitioners recognizing alcohol dependence: a large cross-sectional study in six European countries. Ann Fam Med. 2015;13:28–32.

36. Thomasson H. Gender Differences in Alcohol Metabolism. In: Recent Developments in Alcoholism. Volume 12, edn. Edited by Galanter M, Begleiter H, Dietrich R, Gallant D, Goodwin D, Gotthiel E, Paredes A, Rothschild M, Van Thiel D, Edwards H. Springer US; 1995: 163–179.

37. Agence Technique de l’Information sur l’Hospitalisation. Le décès dans le PMSI-MCO : validation et précautions d’utilisation. [Death in acute care: validation and precaution instructions]. Agence Technique de l’Information sur l’Hospitalisation, 2010. http://www.ath.sante.fr/etude-du-mode-de-sortie-deces-sur-les-donnees-pmsi-mco-de-2008. Accessed 08/16/2016.

38. Répartition des décès selon le lieu du décès [Distribution of deaths according to location] [http://insee.fr/fr/themes/detail.asp?reg_id=4&ref_id=ir-inoscd2013#IRSOCSD2013_SERIE] Accessed 08/16/2016.

39. Schomerus G, Holtzinger A, Matschinger H, Lucht M, Angermeyer MC. Public attitudes towards alcohol dependence an overview. Psychiatr Prax. 2010;37:111–8.

40. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Use of mental health services in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109:47–54.

41. Rehm J, Anderson P, Barry J, Dimitrov P, Elekes Z, Fejő F, et al. Prevalence of and potential influencing factors for alcohol dependence in Europe. Eur Addict Res. 2015;21:6–18.

42. Boyle P. Alcohol consumption and breast cancer risk. In: Alcohol: Science, Policy, and Public Health. edn. Edited by Boyle P, Bofetta P, Lowenfels AB, Bums H, Brawley O, Zatonski W, Rehm J, Oxford, U.K.: Oxford University Press; 2013: 234–240.

43. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112:580–93.

44. Hemajima N, Hirose K, Tajima K, Rohan T, Calle E, Heath C, et al. Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87:1234–45.

45. Roerecke M, Gual A, Rehm J. Reduction of alcohol consumption and subsequent mortality in alcohol use disorders: systematic review and meta-analysis. J Clin Psychiatry. 2013;74:e181–9.

46. Babor TF, Higgins-Biddle JC. Brief intervention - for hazardous and harmful drinking. A manual for use in primary care. World health organization: Geneva, Switzerland, 2001.

47. McQueen J, Howe TE, Allan L, Mains D, Hardy V. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. 2011;8:CD005191.

48. Ragausis JM. Alcohol screening in the acute care hospital. J Addict Nurs. 2004;15:171–5.

49. Anderson P, Bendtsen P, Spak F, Reynolds J, Drummond C, Segura I, et al. Improving the delivery of brief interventions for heavy drinking in primary health care: outcome results of the optimizing delivery of health care intervention (ODHIN) five-country cluster randomized factorial trial. Addiction. 2016;111:1935–45.

50. World Health Organization. Global strategy to reduce the harmful use of alcohol. Geneva: World Health Organization; 2010.

51. Anderson P, Bradlick F, Conrod P, Gual A, Hellman M, Matrai S, et al. The new governance of addictive substances and behaviours. Oxford, U.K.: Oxford University Press; 2017.